- Home
- ILPT vs DSGN Comparison
ILPT vs DSGN Comparison
Compare ILPT & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ILPT
- DSGN
- Stock Information
- Founded
- ILPT 2017
- DSGN 2017
- Country
- ILPT United States
- DSGN United States
- Employees
- ILPT N/A
- DSGN N/A
- Industry
- ILPT Real Estate Investment Trusts
- DSGN Biotechnology: Pharmaceutical Preparations
- Sector
- ILPT Real Estate
- DSGN Health Care
- Exchange
- ILPT Nasdaq
- DSGN Nasdaq
- Market Cap
- ILPT 315.4M
- DSGN 264.4M
- IPO Year
- ILPT 2018
- DSGN 2021
- Fundamental
- Price
- ILPT $4.61
- DSGN $5.00
- Analyst Decision
- ILPT Buy
- DSGN Hold
- Analyst Count
- ILPT 2
- DSGN 3
- Target Price
- ILPT $10.00
- DSGN $7.00
- AVG Volume (30 Days)
- ILPT 386.8K
- DSGN 458.2K
- Earning Date
- ILPT 10-29-2024
- DSGN 11-11-2024
- Dividend Yield
- ILPT 0.87%
- DSGN N/A
- EPS Growth
- ILPT N/A
- DSGN N/A
- EPS
- ILPT N/A
- DSGN N/A
- Revenue
- ILPT $441,893,000.00
- DSGN N/A
- Revenue This Year
- ILPT N/A
- DSGN N/A
- Revenue Next Year
- ILPT $6.87
- DSGN N/A
- P/E Ratio
- ILPT N/A
- DSGN N/A
- Revenue Growth
- ILPT 3.28
- DSGN N/A
- 52 Week Low
- ILPT $2.22
- DSGN $1.96
- 52 Week High
- ILPT $5.45
- DSGN $6.91
- Technical
- Relative Strength Index (RSI)
- ILPT 38.92
- DSGN 46.65
- Support Level
- ILPT $4.52
- DSGN $4.51
- Resistance Level
- ILPT $4.97
- DSGN $5.62
- Average True Range (ATR)
- ILPT 0.16
- DSGN 0.33
- MACD
- ILPT -0.05
- DSGN -0.11
- Stochastic Oscillator
- ILPT 13.24
- DSGN 30.25
About ILPT Industrial Logistics Properties Trust of Beneficial Interest
Industrial Logistics Properties Trust is a real estate investment trust. It owns and leases industrial and logistics properties throughout the United States. The company's investment portfolio includes industrial lands in Hawaii and industrial and logistics properties in other states. Rental revenue is earned from Hawaii Properties and Mainland Properties.
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.